CNTB
Connect Biopharma·NASDAQ
--
--(--)
--
--(--)
6.61 / 10
Outperform
Analysts are uniformly bullish, with two strong‑buy ratings, though one analyst’s track record is flat. Fund‑flow metrics are positive overall, especially extra‑large inflows, while small, medium and large segments show outflows. Sentiment score 6.61 reinforces a favorable capital‑flow outlook.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-13
InstitutionBTIG
Times predicted2
Historical Win Rate100.0%
What is the analyst consensus for CNTB?
- CNTB holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.61/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
